Pieris Pharmaceuticals (PIRS) Given a $9.00 Price Target by HC Wainwright Analysts

HC Wainwright set a $9.00 price objective on Pieris Pharmaceuticals (NASDAQ:PIRS) in a report published on Wednesday. The firm currently has a buy rating on the biotechnology company’s stock.

Separately, ValuEngine lowered Pieris Pharmaceuticals from a hold rating to a sell rating in a report on Friday, December 1st. One analyst has rated the stock with a sell rating and four have issued a buy rating to the stock. The company presently has a consensus rating of Buy and an average price target of $9.00.

Shares of Pieris Pharmaceuticals (NASDAQ PIRS) traded up $0.08 during trading on Wednesday, hitting $5.93. The stock had a trading volume of 492,900 shares, compared to its average volume of 614,524. Pieris Pharmaceuticals has a fifty-two week low of $1.38 and a fifty-two week high of $6.65.

Pieris Pharmaceuticals (NASDAQ:PIRS) last announced its quarterly earnings results on Wednesday, November 8th. The biotechnology company reported ($0.16) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.21) by $0.05. The business had revenue of $3.93 million during the quarter, compared to analyst estimates of $1.52 million. Pieris Pharmaceuticals had a negative return on equity of 221.93% and a negative net margin of 321.83%. Pieris Pharmaceuticals’s quarterly revenue was up 400.3% on a year-over-year basis. sell-side analysts anticipate that Pieris Pharmaceuticals will post -0.72 earnings per share for the current year.

In related news, major shareholder Orbimed Advisors Llc sold 147,635 shares of the business’s stock in a transaction that occurred on Monday, December 18th. The stock was sold at an average price of $5.70, for a total value of $841,519.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 4.05% of the stock is currently owned by insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of PIRS. Voya Investment Management LLC acquired a new stake in Pieris Pharmaceuticals in the 2nd quarter worth approximately $100,000. Wells Fargo & Company MN acquired a new stake in Pieris Pharmaceuticals in the 3rd quarter worth approximately $105,000. State of Wisconsin Investment Board acquired a new stake in Pieris Pharmaceuticals in the 2nd quarter worth approximately $132,000. The Manufacturers Life Insurance Company lifted its holdings in Pieris Pharmaceuticals by 1,106.3% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 31,785 shares of the biotechnology company’s stock worth $161,000 after purchasing an additional 29,150 shares during the last quarter. Finally, Rhumbline Advisers acquired a new stake in Pieris Pharmaceuticals in the 2nd quarter worth approximately $184,000. Hedge funds and other institutional investors own 50.45% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Pieris Pharmaceuticals (PIRS) Given a $9.00 Price Target by HC Wainwright Analysts” was reported by Community Financial News and is the sole property of of Community Financial News. If you are reading this article on another site, it was illegally stolen and republished in violation of international copyright & trademark law. The correct version of this article can be accessed at https://www.com-unik.info/2017/12/21/pieris-pharmaceuticals-pirs-given-a-9-00-price-target-by-hc-wainwright-analysts.html.

About Pieris Pharmaceuticals

Pieris Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids.

Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit